跳至主要内容
临床试验/NL-OMON51129
NL-OMON51129已完成不适用

Cardionomic Cardiac Pulmonary Nerve Stimulation Pilot Study - CPNS Pilot Study

Cardionomic Inc0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Subjects must meet all the following inclusion criteria to be eligible to
  • participate in this study:
  • 1. At least 18 years of age, or older if required by local law
  • 2. Admitted to the hospital with a principal diagnosis of acute decompensated
  • heart failure.
  • 3. BMI adjusted BNP >= 500 pg/mL or NT-pro-BNP >= 2000 pg/mL; 4% reduction in
  • BNP/NT-proBNP for every increase of 1 kg/m2 in BMI above a reference of 20kg/m2
  • (Refer to Appendix B: BNP/NT-proBNP corrected for BMI)
  • 4. Left ventricular ejection fraction <= 45%; documented within previous 12
  • 5. At least one sign or symptom of fluid overload
  • 6. At least one of the following:
  • o Persistent inadequate diuretic response
  • o At least one sign or symptom of low perfusion

排除标准

  • 1. First IV treatment upon presentation in hospital to randomization is > 48
  • 2. Received an inotrope during current hospitalization or anticipated to
  • receive an inotrope in the 12 hours following enrollment
  • 3. Requires mechanical support (e.g., mechanical circulatory support,
  • ultrafiltration) or anticipated to receive mechanical support in the 12 hours
  • following enrollment
  • 4. Manually measured systolic blood pressure < 80 mmHg at screening
  • 5. Manually measured systolic blood pressure > 130 mmHg at screening
  • 6. Symptomatic hypotension
  • 7. eGFR < 25 mL/min/1.73m2
  • 8. Has an active infection
  • 9. Has an active or passive implantable device that may interfere with CPNS
  • therapy per physician discretion
  • 10. Has a cardiac resynchronization therapy (CRT) device or a pacemaker
  • 11. Has an implantable cardioverter defibrillator (ICD) and is pacemaker
  • dependent or has had a sustained VT/VF episode in the previous 90 days (a
  • subject can be enrolled if he/she meets this criterion, the physician deems it
  • appropriate to suspend therapies during hospitalization and leads have been
  • implanted for at least six months prior to the study procedure) 12. Permanent
  • or persistent atrial fibrillation with uncontrolled ventricular response
  • (ventricular rate > 125 BPM) at time of enrollment
  • 13. Unstable angina or documented myocardial infarction within last 30 days
  • 14. Prior heart transplant
  • 15. History of severe mitral or aortic stenosis or regurgitation
  • 16. History of pulmonary embolism within the last 6 months
  • 17. History of hyper-coagulation disorders
  • 18. History of more than one CABG procedure
  • 19. History of severe pulmonary hypertension (pulmonary arterial systolic
  • pressure >= 75 mmHg)
  • 20. Diagnosis of primary pulmonary hypertension
  • 21. Diagnosis of congenital heart disease
  • 22. Participating in concurrent trial unless approved by Cardionomic study
  • 23. Pregnant or childbearing age and not on reliable form of birth control
  • 24. Allergy to nickel, fentanyl, midazolam, propofol, heparin, eggs, egg
  • products, soybeans or soy products
  • 25. Unwilling or unable to provide consent
  • 26. Exclusion criteria by local law (e.g., age, prisoner, etc)

研究者

相似试验